|
Michael D. Lesh, MD
Michael D. Lesh, MD, founder, chairman and CEO, is a physician, scientist and entrepreneur. He earned undergraduate and graduate degrees in computer science and bioengineering from the Massachusetts Institute of Technology before entering medical school at the University of California San Francisco. After completing internal medicine training at UCSF and cardiology and cardiac electrophysiology training at the Hospital of the University of Pennsylvania, he joined the faculty at UCSF, where he was Chief of Cardiac Electrophysiology. Dr. Lesh's research spanned a wide range from bench to bedside. He pioneered a number of procedures for catheter ablation of cardiac arrhythmias, and is the author of over 300 scientific papers, book chapters and books. Dr. Lesh holds over 100 patents issued or pending.
Since 1997, Dr. Lesh has founded three successful medical device companies based on his inventions. Johnson and Johnson (JNJ) acquired his first venture, Atrionix, developer of a novel ultrasound ablation catheter for atrial fibrillation. Dr. Lesh founded and was Chairman and CEO of Mitralife, which developed a catheter-based treatment for mitral valve disease and CHF; and Appriva, which developed PLAATO, a percutaneous trans-catheter device for preventing stroke. Mitralife and Appriva were acquired by ev3, Inc.
With Evera, Dr. Lesh has taken advanced technology available from cardiovascular device engineering and applied to devices for aesthetic enhancement.
Michael Fraunces
Michael Fraunces is President and General Counsel of Md7, LLC, a wireless services company assisting major carriers with reducing operating expenses through renegotiation of existing cellular leases.
Prior to joining Md7, Mr. Fraunces founded JurisVenture, P.C., a law firm providing specialized expertise to entrepreneurial enterprises. Before that, Mr. Fraunces was a partner in the business department of both Pillsbury Winthrop Shaw Pittman, LLP, and Luce, Forward, Hamilton & Scripps, LLP.
Mr. Fraunces is an expert in corporate transactional law, having participated in over 50 mergers and acquisitions and a like number of public and private financing transactions. Mr. Fraunces has served as outside general counsel to a host of small to medium-sized private technology-oriented companies and the various constituents of such companies, including investors, corporate partners and boards of directors.
Mr. Fraunces graduated from UC Berkeley in 1984 then served five years as an officer in the United States Navy aboard nuclear-powered submarines.
Following his Naval service, Mr. Fraunces attended the Yale Law School, where he was also the Managing Editor of the Yale Law Journal.
Jerry C. Griffin
Jerry C. Griffin, MD, is president of Griffin & Schwartz, Scientific Services, Inc. a management consulting firm in the healthcare products field. Dr. Griffin has assisted several investment firms and development stage companies providing consulting services for venture and public financing, and FDA and clinical trial strategy including serving as interim CEO. He is currently a member of the Boards of Directors of two public and four private companies. From 1999-2006 Dr. Griffin was President, CEO and a Director of POINT Biomedical Corp. where he led the company through the clinical development and submission of a New Drug Application (NDA) to the FDA for a novel pharmaceutical agent for ultrasound myocardial perfusion. Prior to joining POINT, Dr. Griffin, was Executive Vice President of InControl, Inc., a cardiovascular medical device company. Dr. Griffin was responsible for overseeing InControl’s clinical and regulatory programs and establishing a worldwide strategy for its devices for treating atrial fibrillation, a major cardiovascular disorder. InControl was acquired by the Guidant Corporation in September, 1998. Dr. Griffin was Professor of Medicine at the University of California at San Francisco and held a faculty position there from 1984 to 1995. He also served on the faculties of Stanford University Medical School and Baylor College of Medicine. During his academic tenure he held leadership positions in several national and international cardiology organizations and is the author or co-author of 5 books, 4 patents, and over 170 medical and scientific articles. He holds a B.S. degree from the University of Southern Mississippi, an M.D. degree from the University of Mississippi School of Medicine, and received his Cardiology training at Stanford University Medical Center.
Glen D. Nelson
Glen D. Nelson, MD, is chairman of GDN Holdings, LLC (Aviation, Health Services and Medical Devices). Prior to GDN Holdings, Dr. Nelson was Vice Chairman of Medtronic, Inc., from 1988 until his retirement in 2002. He served on the Medtronic Board of Directors from 1980-2002. Before joining Medtronic, Dr. Nelson practiced surgery from 1969-1986. He was Chairman, President and Chief Executive Officer of the Park Nicollet Medical Center from 1975-1986. He was also Chairman and Chief Executive Officer of American MedCenters, Inc., from 1984-1986.
Dr. Nelson currently serves on a number of Boards of both private and public companies, including Advanced BioSurfaces, Inc., Angiotech Pharmaceuticals, Inc., Cardiovascular Systems, Inc., DexCom, Inc., Guided Delivery Systems, Inc., Regent Aviation, and Reliant Technologies, Inc.
Dr. Nelson received a Bachelor of Arts degree from Harvard College in 1959, and a doctor of medicine degree from the University of Minnesota in 1963. He completed his training in general surgery at Hennepin County General Hospital, Minneapolis, in 1969. Dr. Nelson was certified by the American Board of Surgery in 1970.
|
|
 |
